PerkinElmer, Inc.(PKI) Stock Research - Grey Stern Research

PerkinElmer, Inc. (PKI) Stock Analysis

$115.24 (-0.91%)

PKI Financial Performance


Use the table below to view PerkinElmer, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $115.24 -
52 Week Low $113.17 -
52 Week High $170.00 -
Market Cap $14.5 Billion 11/13
Gross Margin 56% 6/13
Profit Margin 11% 7/13
EBITDA margin 30% 5/13
Q2 - 2024 Revenue $691.7 Million 12/13
Q2 - 2024 Earnings $79.1 Million 11/13
Q2 - 2024 Free Cash Flow $136.6 Million 10/13
Trailing 4 Quarters Revenue $2.7 Billion 12/13
Trailing 4 Quarters Earnings $193.2 Million 11/13
Quarterly Earnings Growth 122% 2/13
Annual Earnings Growth 75% 1/13
Quarterly Revenue Growth -2% 7/13
Annual Revenue Growth -1% 7/13
Cash On Hand $1.2 Billion 5/13
Short Term Debt $711.4 Million 7/13
Long Term Debt $3.2 Billion 5/13

PerkinElmer, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare PerkinElmer, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 74.83 2/13
PS 5.34 7/13
PB 1.84 12/13
PC 11.58 13/13
Liabilities to Equity 0.71 11/13
ROA 0.01 11/13
ROE 0.02 11/13
Current Ratio 2.42 2/13
Quick Ratio 0.35 1/13
Long Term Debt to Equity 0.40 7/13
Debt to Equity 0.51 9/13
Burn Rate 5.54 5/13
Cash to Cap 0.09 1/13
CCR 1.73 2/13
EV to EBITDA 82.41 7/13
EV to Revenue 6.35 6/13

Company Details

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

CEO: Mr. Prahlad Singh

Website: https://www.perkinelmer.com

Address: 940 Winter St Boston, MASSACHUSETTS

Exchange: New York Stock Exchange

Industry: Diagnostics & Research

PerkinElmer, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to PerkinElmer, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Agilent Technologies, Inc. A $42.1 Billion
Danaher Corporation DHR $197.8 Billion
Thermo Fisher Scientific Inc. TMO $234.1 Billion
Illumina, Inc. ILMN $22.1 Billion
Laboratory Corporation of America Holdings LH $18.4 Billion
IDEXX Laboratories, Inc. IDXX $40.0 Billion
IQVIA Holdings Inc. IQV $42.2 Billion
Waters Corporation WAT $21.1 Billion
Charles River Laboratories International, Inc. CRL $10.0 Billion
Mettler-Toledo International Inc. MTD $32.0 Billion
ICON Public Limited Company ICLR $24.4 Billion
Sotera Health Company SHC $4.6 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
PKI Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 691.7 Million $79.1 Million
Q1 2024 $ 649.9 Million $26.0 Million
Q4 2023 $ 695.9 Million $78.6 Million
Q3 2023 $ 670.7 Million $9.5 Million
Q2 2023 $ 709.1 Million $35.6 Million
Q1 2023 $ 674.9 Million $24.8 Million
Q4 2022 $ 741.2 Million $107.5 Million
Q3 2022 $ 711.8 Million $85.3 Million

View All

PKI Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $1.2 Billion $13.4 Billion $4.0 Billion $7.9 Billion
Q1 2024 $999.5 Million $13.4 Billion $4.0 Billion $7.8 Billion
Q4 2023 $914.4 Million $13.6 Billion $4.0 Billion $7.9 Billion
Q3 2023 $1.1 Billion $13.4 Billion $4.0 Billion $7.7 Billion
Q2 2023 $1.3 Billion $14.2 Billion $4.5 Billion $7.9 Billion
Q1 2023 $2.3 Billion $14.6 Billion $4.5 Billion $8.0 Billion
Q4 2022 $454.4 Million $14.1 Billion $4.6 Billion $7.4 Billion
Q3 2022 $400.7 Million $13.8 Billion $4.5 Billion $7.1 Billion

View All

PKI Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $136.6 Million -$22.0 Million $250.0 Million
Q1 2024 $129.7 Million -$17.8 Million $85.1 Million
Q4 2023 $172.5 Million -$24.1 Million -$222.3 Million
Q3 2023 -$55.8 Million -$22.4 Million -$195.4 Million
Q2 2023 -$149.3 Million -$13.9 Million -$935.2 Million
Q1 2023 $42.5 Million -$20.9 Million $1.8 Billion
Q4 2022 $113.0 Million -$26.1 Million $54.4 Million
Q3 2022 $146.9 Million -$13.1 Million $54.4 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions